RecruitingPhase 1NCT05748197
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Studying Cerebrotendinous xanthomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Jae Park, MDMemorial Sloan Kettering Cancer Center
- Intervention
- ADCLEC.syn1 CAR T cells(biological)
- Enrollment
- 40 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (7)
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Collaborators
Takeda
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05748197 on ClinicalTrials.govOther trials for Cerebrotendinous xanthomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07510802Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCBeijing Biotech
- RECRUITINGPHASE1NCT07162038Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationNational Cancer Institute (NCI)
- RECRUITINGNANCT06790225Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)Esbjerg Hospital - University Hospital of Southern Denmark
- RECRUITINGPHASE2NCT05909059CAR T-cell Therapy in Patients With Renal DysfunctionNorthside Hospital, Inc.
- RECRUITINGPHASE2NCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialCity of Hope Medical Center
- RECRUITINGPHASE1, PHASE2NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE3NCT05883852EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerFudan University
- ACTIVE NOT RECRUITINGPHASE1NCT05627323CAR T Cells in Patients With MMP2+ Recurrent or Progressive GlioblastomaChimeric Therapeutics